Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced a four year collaborative research agreement to establish ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE